Stryker Corporation (SYK)

Health Care · $122B market cap · SEC CIK 0000310764

Next reports on Jan 27, 2027, after the close, with analysts expecting $5.06 in earnings per share.

52-week range $267.00 to $389.33. 17% below its 52-week high and 21% above its low.

The case for SYK

• Generated $4.3B of free cash flow in FY2025, 17% of revenue.
• Has compounded revenue at 11.8% a year over five years.
• Return on equity of 16%.
• Gross margin of 66% absorbs cost shocks.
• Moves less than the market (beta 0.74).
• Current assets cover the near-term bills 2.2 times over.

The case against

• Pricey for its growth: 33.6× earnings, where 12% a year of growth plus a 1.0% dividend would justify about 27×.
• The price trend is weak (40/100): −8.5% over a year, −5.8% over three months, 17% below its 52-week high.
• Trailed the S&P 500 by 21 points over the past year.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Stryker Corporation's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Stryker Corporation says it does

Stryker Corporation (Stryker or the Company) is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our core values guide our behaviors and actions and are fundamental to how we execute our mission. Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a prominent orthopaedic surgeon and inventor of several medical products. Our products are sold in approximately 61 countries through company-owned subsidiaries and branches as well as third-party dealers and distributors, and include surgical equipment and surgical navigation systems; endoscopic and communications systems;…

Risk factors SYK lists in its 10-K

• We use a variety of raw materials, components, devices and
• third-party services in our global supply chains, production
• and distribution processes; significant shortages, price
• increases or unavailability of third-party services have in the
• past increased, and could in the future increase, our
• operating costs and could require significant capital
• expenditures or adversely impact the competitive position of
• We are subject to pricing pressures as a result of cost
• containment measures in the United States and other
• countries and other factors, including changes in
• reimbursement practices and coverage policies and third-
• party payor cost containment measures
• Dollar amounts in millions except per share amounts or as otherwise specified
• We operate in a highly competitive industry in which
• competition and the regulatory burden in the development
• and improvement of new and existing products is
• We may be unable to maintain adequate working
• relationships with healthcare professionals
• We rely on indirect distribution channels and major
• distributors that are independent of Stryker
• We may be unable to capitalize on previous or future
• We, our business partners or our third-party vendors could
• experience a material failure or breach of a key information
• technology system, network, process or site
• An inability to successfully manage the implementation of
• our new commercial global enterprise resource planning
• (ERP) system could adversely affect our operations and
• We may be unable to attract, develop and retain executives
• Interruption of manufacturing operations could adversely
• Our insurance program may not be adequate to cover future
• We have experienced, and may continue to experience, a
• significant and unpredictable need to adjust our operations
• as market demand for certain of our products has shifted
• and continues to shift or as may be mandated by
• Our use of AI and other emerging technologies could
• adversely impact our business and financial results
• Pandemics and public health emergencies, and the fear
• thereof, have in the past materially adversely affected and
• could in the future materially adversely affect, our
• operations, supply chain, manufacturing, product
• distribution, customers and other business activities
• Current economic and political conditions make tax rules in
• jurisdictions subject to significant change
• We could be negatively impacted by future changes in the
• allocation of income to each of the income tax jurisdictions
• The impact of healthcare reform legislation on our business
• We are subject to extensive governmental regulation relating
• to the classification, manufacturing, sterilization, licensing,
• labeling, marketing and sale of our products
• We are subject to federal, state and foreign healthcare
• regulations, including anti-bribery, anti-corruption, anti-
• kickback and false claims laws, globally and could face
• substantial penalties if we fail to comply with such
• We are subject to privacy, data protection and data security
• regulations and laws globally, and could face substantial
• penalties if we fail to comply with such regulations and laws
• We may be adversely affected by product liability claims,
• unfavorable court decisions or legal settlements
• Intellectual property litigation and infringement claims could
• cause us to incur significant expenses or prevent us from
• Dependence on intellectual proprietary rights and failing to
• protect such rights or to be successful in litigation related to
• such rights may impact offerings in our product portfolios
• Additional capital that we may require in the future may not
• be available to us or may only be available to us on
• unfavorable terms, which could negatively affect our
• We could be negatively impacted by evolving requirements
• and expectations related to corporate responsibility and
• sustainability-related matters, including those related to
• Physical weather events, as well as legal, regulatory or
• market measures related to environmental, climate and other
• sustainability matters, could adversely affect our operations

Filings

Other Health Care companies